Kornimate/medical-research-clean huggingface dataset:
severe complications after gastrectomy for esophagogastric junction and gastric cancer

Conditions: Gastric Cancer; Esophagogastric Junction Disorder

Summary: gastrectomy is the main treatment for gastric and siewert type ii-iii esophagogastric junction (egj) cancer. this surgery is associated with significant morbidity. the aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications. this is a retrospective cohort study.

gastrectomy is the main treatment for gastric and siewert type ii-iii esophagogastric junction (egj) cancer. this surgery is associated with significant morbidity. the aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications. this was a retrospective cohort study. the investigators included patients treated with gastrectomy for gastric or egj cancers at a single center. severe morbidity was defined as clavien-dindo score ≥3. the following factors are analyzed: age, sex, comorbidity, american society of anesthesiologists (asa) physical status, tobacco and alcohol consumption, body mass index (bmi), hematocrit, serum albumin level, tumor location, the use of preoperative chemotherapy, laparoscopic or open surgery, total or subtotal gastrectomy, duodenal stump closure, multi-organ resection, lymphadenectomy, reconstruction method, t status, lymph node metastasis, and resection margin. the t stage was grouped by t1-t2 and t3-t4 for analysis. patients will be followed for 5 years after surgery for survival analysis. a multivariate analysis is performed to identify predictors of overall and severe morbidity; and predictors of long-term survival.

Eligibility criteria:
inclusion criteria: * patients treated with a gastrectomy for gastric cancer or esophagogastric cancer. * confirmed adenocarcinoma histology. exclusion criteria: * histology different from adenocarcinoma.

Keywords: stomach neoplasms gastrectomy risk factors morbidity adenocarcinoma
exercise trial in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: chronic kidney disease (ckd) is exceedingly common in older adults, in whom it is associated with impairment in cognition and physical function. the purpose of this study is to test the effects of 12 months of aerobic and resistance exercise training compared to health education on cognitive and physical performance in 120 older adults with ckd not requiring dialysis. the results of this study will be essential for demonstrating the effectiveness of exercise in improving function and ultimately preventing disability in this high-risk population of older adults.

this is a parallel-group randomized controlled trial comparing 12 months of aerobic and resistance exercise training vs. health education (attention control) on neurocognitive and physical performance among community-dwelling older adults (age \>55) and ckd stage 3b and 4. co-primary outcomes are change in physical performance (including aerobic capacity and submaximal walking) and neurocogntive performance (including executive functions). outcome measures will be assessed at baseline and after 6- and 12 months. exercise training will occur thrice weekly at a dedicated research exercise center and will be supervised by exercise specialists.

Eligibility criteria:
inclusion criteria: * stage 3-4 chronic kidney disease (estimated glomerular filtration rate 15-45) * age 60 to 85 * english speaking exclusion criteria: * dementia or cognitive impairment * renal transplant * new york heart association class 3-4 heart failure * severe chronic lung disease * unstable angina or coronary revascularization within the last 3 months * orthopedic problems that would preclude aerobic exercise training * known, untreated infection * disabling arthritis * uncontrolled arrhythmia * more than 14 alcoholic drinks per week

Keywords: chronic kidney disease exercise aerobic capacity learning and memory executive function endothelial function
effectiveness of aquatic theraphy in spasticity: watsu and halliwick

Conditions: Brain-injury

Summary: treatment with acd patients will be carried out through the application of aquatic therapies, being the halliwick concept and the watsu method together with a time of immersion in hot water.

the study consists of verifying the efficacy of physiotherapeutic treatment through the use of aquatic therapies, watsu and halliwick in subjects who have suffered acquired brain injury (acd), and who, after that, present spasticity. for this, the users of the brain injury association of cádiz (adacca) are taken as references. brain damage is a brain injury, resulting in a series of functional and neurological alterations. the treatment of this pathology will be carried out through the application of aquatic teràpies, being the halliwick concept and the watsu method. this study consists of a clinical trial where the experimental group will be applied the combined treatment of halliwick and watsu together with a time of immersion in hot water, and to the control group the treatment by halliwick plus immersion in hot water, in order to evaluate the degree of spasticity they present at the end of the study.

Eligibility criteria:
inclusion criteria: * belonging to the acquired brain injury association of cádiz * presence of spasticity in the biceps brachii and soleus muscles confirmed by the modified ashworth scale and modified tardieu scale. * patients who are standing and walking at least with technical assistance and / or supervision. * patients with acquired brain damage and with spastic hemiparesis with a chronic evolution of more than 12 months. exclusion criteria: * presence of infections. * other diagnosed diseases that prevent aquatic physiotherapy treatment, such as uncontrolled diabetes or dyspnea at rest. * have received aquatic therapy treatment in the six months prior to the study with the methods developed in the study (halliwick or watsu).

Keywords: acquired brain damage aquatic therapy hemiparesis spasticity
transcriptome study of acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: this study aims to compare whole-blood microarray gene-expression profiling between patients with acute myocardial infarction and normal participants without cardiovascular diseases. firstly, screening differentially genes of mrna to perform gene ontology and pathway analysis. secondly, predicting target genes regulated by microrna and constructing coexpression network with mrna. thirdly, biological function experiment of microrna. finally, revealing pathogenic mechanisms associated with acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * ami patients: 1. 20-50 years of age 2. symptoms of ischaemia 3. new significant st-segment-t wave changes in ecg and definitive diagnosis of non-st elevation mi or st elevation mi 4. cardiac troponin with at least one value above the 99th percentile upper reference limit * normal control participants: 1. 20-50 years of age 2. normal ecg 3. bmi \<24kg/m2 4. systolic blood pressure \<140mmhg 5. diastolic blood pressure \<90mmhg 6. total cholesterol \<200mg/dl (5.18mmol/l) 7. triglyceride \<150mg/dl (1.70mmol/l) 8. high density lipoprotein cholesterol \>=40mg/dl (1.04mmol/l) 9. low density lipoprotein cholesterol \<130mg/dl (3.37mmol/l) 10. fasting blood glucose \<100mg/dl (5.6mmol/l) 11. not taking antihypertensive or hypolipidemic or hypoglycemic drugs exclusion criteria: 1. cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ecg changes, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased 2. prior myocardial infarction 3. percutaneous coronary intervention related mi 4. stent thrombosis associated with mi 5. coronary artery bypass grafting related mi 6. recurrent mi or reinfarction 7. myocardial injury with necrosis caused by transcatheter aortic valve implantation or mitral clip or ablation of arrhythmias 8. myocardial injury or infarction associated with heart failure 9. myocardial infarction in the intensive care unit 10. other diseases: previous history of ascvd, cancer, rheumatoid arthritis, liver or kidney disease, myeloproliferative disorders, chronic inflammation, peripheral vascular disease 11. not available informed consent
effectiveness and safety of pharmacopuncture therapy for patients with lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: this is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the conservative treatments including physiotherapy and pharmacological treatments.

this is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the conservative treatments including physiotherapy and pharmacological treatments. the physician will decide specific location, type, and doses of pharmacopuncture therapy or conservative treatments according to each participants' disease conditions, respectively. the researcher will record concurrently.

Eligibility criteria:
inclusion criteria: 1. diagnosed with lumbar spinal stenosis based on radiology including computed tomography or magnetic resonance imaging. 2. clear neurogenic claudication symptoms existed (symptoms aggravated with walking, and alleviated upon resting in lumbar flexion position). 3. reported radiating leg pain or low back pain (lbp) with intensity of nrs ≥5 4. between the age of 19 and 69 years old. 5. participants who agreed to participate the study and voluntarily signed the informed consent form. exclusion criteria: 1. patients with vascular claudication 2. patients with pathologies of non-spinal origin that may cause lbp or radiating leg pain (e.g. spinal tumor, fracture) 3. patients with soft tissue pathologies that may cause lbp or radiating leg pain (e.g. tumor, fibromyalgia, rheumatoid arthritis, gout) 4. patients with other systemic diseases that may interfere with treatment effect or outcome interpretation 5. patients who administrate those prescribed medicine that may interfere with interpretation of the result (e.g. corticosteroids, immunosuppressants, physchotropic drugs) 6. patients for whom pharmacopuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, serious diabetes with risk of infection) 7. patients who were treated with one of the following intervention within the past week; medicine that may potentially influence pain such as nsaids (nonsteroidal antiinflammatory drugs), pharmacopuncture, or physical therapies. 8. pregnant patients or patients planning pregnancy 9. patients with medical history of spinal surgery within the past 3 months 10. previous participation in other clinical studies within 1 month of current study enrollment, or plans to participate in other clinical studies during participation (including follow-up period) of the current study after study enrollment 11. patients unable to fill out study participation consent form 12. patients deemed unsuitable for study participation as assessed by the researchers
propess versus prostin for induction of labour in women with term prom

Conditions: Premature Rupture of Membranes at Term; Induction of Labour

Summary: premature rupture of membranes (prom) at term is a rupture that occurs at term (\> 37 weeks) before the start of labor. the purpose of the study was to compare the safety and efficacy of two agents used in induction of labor in women with term prom propess (controlled release dinoprostone, vaginal delivery system) and prostin e2 (dinoprostone vaginal tablet). women will be randomised to two treatment groups. although some studies support efficacy of the propess for cervical ripening at term in induction of labor with intact membranes, it has not been well studied in women with prom at term.

the study is going to include all pregnant women with in-term prom (after week 37 of pregnancy) without contractions if they meet the inclusion criteria. if the cervix is still non-inducible after 4-6 hours and there are no contractions, the medication to be administered to them will be determined by means of computer randomization. the success rate of induction with propess vs. prostin tablets will be compared. soon after prom, there can be the onset of contractions and cervix dilation that lead to childbirth. in case of some pregnant women, there are no contractions and cervix dilation even after the event despite prom and water breaking. if the status remains unchanged, the risk of intrauterine infection, fetus infection, and later on an infection of the newborn increases. the expecting mother can also eventually lose hope for a successful vaginal birth and starts thinking about having a caesarean delivery. to avoid that, the investigators use medications that accelerate the onset of vaginal birth in clinical practice. the investigators know several ways to induce labour after prom. references give no clear and reliable data on the best approach. the investigators can use medications such as oxytocin, dinoprostone, or misoprostol. our ward has been using prostin 3 mg (dinoprostone) vaginal tablets to induce labour in case of prom for several years. they have proven to be an efficient and safe procedure in our clinical practice. propess is used for the induction of labor with intact membranes. based on the information from references and according to our experience, the medication is highly effective and safe, as well as easy to use. our study aims at establishing whether it can also be used with pregnant women with prom.

Eligibility criteria:
inclusion criteria: * age 18 years or older * gestational age 37 weeks or more * singleton pregnancy * cephalic presentation * unfavorable cervix (bishop \<6) * no contraindications for vaginal delivery * without uterine surgery * without chorioamnionitis exclusion criteria: * age less than 18 years * multiple gestation * previous cesarean section * suspected intraamniotic infection * any contraindication to vaginal delivery * bishop score \>7 * pathological ctg

Keywords: induction prom propess prostin
de-implementation of outdated colonoscopy surveillance interval recommendations among patients with low-risk adenomas

Conditions: Polyp of Colon

Summary: the purpose of this study is to compare the effectiveness of three standard of care outreach approaches (i.e., mailed letter, secure message, and telephone call) on patient adoption of the new 10-year colonoscopy surveillance interval recommendation for a random sample of health plan members who have a now-outdated 5-year surveillance interval due to a finding of 1-2 small adenomas at their prior colonoscopy. the primary study endpoint is the proportion of patients in each outreach arm who adopt the new 10-year colonoscopy surveillance interval.


Eligibility criteria:
inclusion criteria: * kaiser permanente northern california (kpnc) membership\>12 months * primary medical center is either kp san rafael, kp san francisco, kp san leandro, or kp walnut creek * 54-70 years of age at time of 5-year surveillance colonoscopy interval * a baseline colonoscopy with a finding of 1-2 small tubular adenomas and are due for their 5-year surveillance procedure in 2022 * average risk for crc * a valid mailing address, kp.org account (i.e., kpnc's secure messaging portal), and telephone number at time of study enrollment. exclusion criteria: * more than 12 months of membership prior to index colonoscopy, and indications that would make an individual above average risk for crc, such as: adenoma with advanced histology on colonoscopy, adenoma \>10 mm on colonoscopy, family history of crc, prior history of colonoscopy, prior history of adenomas or colon polyp diagnoses, history of ibd, history of hereditary polyposis syndrome, 3 or more adenomas, adenoma 10 mm in size or greater, adenoma with advanced histology, and any sessile serrated polyp or traditional serrated adenoma
economic evaluation of the mewe intervention

Conditions: Depression; Mental Health Issue; Intimate Partner Violence; Domestic Violence; Gender-based Violence; Rape Sexual Assault; Battered Women

Summary: cash transfers have shown promise in preventing intimate partner violence, and in reducing recipients' stress levels. cash transfers with behavioral or psychological interventions have shown limited effectiveness at reducing stress in some african countries. little is known of the cost-effectiveness of interventions delivered alongside cash transfer programs. the mewe economic evaluation sub-study (mewe-ee) runs alongside mewe, a three-arm cluster-randomized controlled trial in sindh, pakistan. mewe-ee will assess the costs and cost-effectiveness of delivering a cash-transfer program (bisp-ct) combined with a life-skills building curriculum (lsb curriculum), compared to the bisp-ct alone. the lsb curriculum is offered to either women who receive bisp-ct, or to women who receive bisp-ct and their husbands.


Eligibility criteria:
inclusion criteria: * in receipt of benazir income support program (bisp) cash transfers (cts) * parity: have at least one child, at least 18 months old exclusion criteria: * plan for the family to migrate out of the village within the next 2 years

Keywords: violence abuse coercion assault aggression gender women girl wife partner spouse sexual physical psychological economic
muscle tissue bank for muscular dystrophy

Conditions: Muscular Dystrophies; Muscular Dystrophy

Summary: this protocol proposes to establish gene expression profiles of muscular dystrophies for correct diagnosis and for development of experimental therapies for these diseases.

muscular dystrophies are caused by mutations in more than 30 genes, some of them remaining to be identified. phenotypically, it is known that one specific mutation can affect the expression of several other proteins causing difficulty in diagnosis. correct genotyping is essential for diagnosis, prognosis and treatment, and relies on a complexed analysis of muscle tissues for phenotype profiles. our research aims to understand how different gene mutations affect expression of other genes via muscle biopsy samples and establishment of phenotypic profiles for correct diagnosis of individual patients. establishment of such information will be critical for understanding the progression of different muscular dystrophies and to devise new experimental therapies. this research will also provide vital clues for finding new genes involved in the disease process. muscle samples may also be used to establish cell cultures for testing drugs and new therapies relevant to the treatment of the muscular dystrophies.

Eligibility criteria:
inclusion criteria: * subjects with or without muscular dystrophy who will be undergoing a diagnostic or therapeutic procedure that involves the removal of a sample of skeletal muscle tissue. * subjects with or without muscular dystrophy who have had a previous skeletal muscle biopsy performed and where a portion of the muscle sample remains in medical storage are also eligible for this study. exclusion criteria: * under age 6

Keywords: muscular dystrophies muscular dystrophy
the experiences of people prescribed opioid pain medicines

Conditions: Pain; Opioid Use

Summary: opioids are morphine-type medicines which come from the opium poppy or are similar-to morphine. they are very effective for short-term pain, cancer pain, and pain at the end of life. opioids are thought to be less useful for treating long-term non-cancer pain. side effects are common and can be serious. people who take opioids for longer periods are at risk of tolerance (needing a higher dose to get the same effect), dependence (unable to cut down or stop without withdrawal effects), and addiction (uncontrollable use despite harmful consequences). in the uk, opioid prescribing has increased substantially over the last two decades. doses are higher and opioids are taken for longer, suggesting many people are at risk of harmful effects without useful pain relief. research into opioid dependence and addiction has found people do not always fully understand the risks of these medicines at the start of treatment. local community pharmacists could be used to improve information and support for those prescribed opioids. this study aims to get a better understanding of the experiences of people prescribed opioids and their information and support needs, and to investigate whether information and support could be improved using community pharmacists. findings may improve care for people prescribed opioids in the future. the study will involve questionnaires and interviews with adults prescribed an opioid medicine for pain, not caused by cancer, over a period of at least 3 months. participants will be recruited from gp practices in england.


Eligibility criteria:
inclusion criteria: * ability to give informed consent * adults aged 18 years and above, with no upper age limit * prescribed any opioid analgesic (defined as any opioid or opioid/paracetamol combination analgesic from sections 4.7.2 and 4.7.1 british national formulary) for non-cancer pain for a period of ≥3 months (defined as ≥ 2 opioid prescriptions issued in the previous 3 months with a minimum interval of 60 days between the first and last prescription) exclusion criteria: * cancer pain * terminal illness * vulnerable patients (e.g. severe mental illness, learning difficulties, dementia, care home residents) * unable to understand english * deemed by their gp to be inappropriate to contact
phase 1 dose finding study of belinostat for treatment of patients with peripheral t-cell lymphoma (ptcl)

Conditions: Peripheral T-cell Lymphoma

Summary: the primary objective of this study is to determine the maximum tolerated dose (mtd) for belinostat when combined with chop regimen and establish the recommended belinostat dose for the phase 3 study.

this is a phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the maximum tolerated dose (mtd) of belinostat when administered in combination with chop.

Eligibility criteria:
inclusion criteria: * age 18 years or above * life expectancy \> 3 months * histologically confirmed diagnosis of ptcl * patients with transformed ctcl eligible for chop regimen * measurable disease based on cheson 2007 criteria * eastern cooperative oncology group (ecog) performance status \< 2 exclusion criteria: * known active hepatitis b/ hepatitis c/ hiv infection * known, uncontrolled cns metastases or primary cns lymphoma * deep vein thrombosis diagnosed within 3 months * ongoing treatment for pre-existing cardiovascular disease * neuropathy grade 3 or more * previous extensive radiotherapy except limited field rt for locally advanced nasal nk ptcl or for pain palliation * prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation * prior therapy with hdac inhibitors (except for ctcl) * inadequate hematological, hepatic, or renal function

Keywords: ptcl maximum tolerated dose belinostat